adnannanu2019
100+ Views

Benefits of Hunza Apricot Kernel?

1. Apricot Kernels are Rich in Fiber, that Supports Digestive Health:
Apricot (Khubani) kernels are composed of 5% fiber each seed! Because they’re full of fiber, consuming them might help support digestive health.
Dietary fiber, or fiber absorbed by eating fruits, vegetables, nuts, and seeds, plays a significant role in the use and health of digestive system organs. Fiber keeps your colon healthy while controlling the digestive tract and processes. Eating a diet high in fiber can improve the regularity of bowel motions and help regulate excess bloating and gas. Fiber frequently utilized to deal with diarrhea, gas, and constipation, and it might be consumed frequently to help prevent digestive irregularities. (Also Read: Benefits of Pistachio Nuts)
2. Apricot Kernel controls Lower Blood Pressure and Improve Heart Health:
Apricot (Khubani) Kernel contains high levels of Thiamine, also known as Vitamin B1, which a study demonstrates may help reduce blood pressure and keep heart health.
Thiamine may promote pump (systolic) and fulfill (diastolic) pressure to and from the heart, possibly helping in preventing congestive heart failure.
New Zealand, results revealed that Thiamine might have favorable effects on lowering the blood pressure levels in people with early-stage hypoglycemia.
Apricot (Khubani) kernels also contain Omega 3, an essential fatty acid that the body Cannot Produce by itself. In accordance with Harvard University, Omega 3 can enhance flow and lower heart rate ( Also Read: Almond Benefits)
3. Apricot Kernel Can Reduce the Effects of Inflammation and Arthritis:
Apricot kernels are Also Be known for Their capability to decrease inflammation. Research proves that the fiber content inside the seeds can trap acid and other toxins in the body and help in their elimination.
Studies show that apricot (Khubani) kernel may even encourage extreme instances of inflammation, such as arthritis.
4. Zinc in Apricot (Khubani) Kernel May Support Vision and Eye Health:
Apricot (Khubani) kernels have a significant quantity of the important trace mineral zinc. Zinc is found in substantial traces in healthy human eyes.
Zinc plays an essential role in transporting Vitamin A into the retina in order to make melanin. Insufficient Zinc was associated with poor night vision, cloudy cataracts, and age-related macular degeneration. Studies show that consuming 40 to 80mg of Zinc every day may impede the progression of esophageal degeneration.
5. Apricot Kernels (Khubani) May Support Liver Health:
Apricot Kernels (Khubani) Can promote liver health and Can Help reverse some of the ramifications of autoimmune hepatitis, a disorder characterized by inflammation of the liver. In a study where mature mice were injected with the virus, the team treated with Apricot Kernel (Khubani) saw major modifications in healthful T-cell growth and a decline in illness.
6. Vitamin B17 Can Boost Immune System Defense:
Vitamin B17 is known for its immune defense properties. Various studies have revealed that B17 might help enhance immunity by slowing the spread of illness throughout the body by killing harmful cells.
7. Apricot Kernel May Support Mental Health:
Omega-3 fatty acids contained in apricot kernels (Khubani) may enhance mental health in adults. Various studies have revealed that omega-3 can decrease mood swings, bipolar episodes, schizophrenia relapses, and violent behavior in people with psychiatric disorders. If you want to Buy Online Hunza Apricot Kernel then Visit HunzaBazar Online Shopping Store.

Read Our Latest Blog - Hunza Gilgit
Buy Online - Hunza Dry Fruits

Are You a Music Lover? Are you interested to download Latest Hindi Songs, Album Songs, Movie Albums, Singer Songs, Latest Punjabi Songs, Pakistani Songs, or Watch & Download Latest Bollywood Videos Songs in High Quality (HD) then Visit UnlimitedMusik.com & Enjoy the latest Hindi Songs?

Comment
Suggested
Recent
Cards you may also be interested in
How COVID-19 Impacted on Neurorehabilitation Devices in Healthcare Industry ?
COVID-19 Impact on Neurorehabilitation Devices in Healthcare Industry OVERVIEW AFTERMATH OF COVID-19 AND GOVERNMENT ROLE The first case of the COVID-19 pandemic was found in Wuhan, China. This pandemic has influenced the whole planet with its major impacts on the economy and businesses across the globe. The COVID-19 spread worldwide in unprecedented ways due to its high infectious and contagious nature. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, Middle East, and Africa up to South America. The COVID-19 has been declared as a pandemic by WHO due to its increased spread across the globe. Various countries announced the complete lockdown just after the declaration of COVID-19 as a pandemic, such as the U.S., India, Germany, and China, to protect them from the spread of the disease. The government imposed lockdown rules, and it had significantly impacted the market. The neurorehabilitation process makes a possible reduction in impairments and disabilities and eventually improves the life of the patient. Examples of neurorehabilitation devices are invasive stimulators, non-invasive stimulators, brain-computer interfaces, and neurorobotics, among others. Current rehabilitation is supported by advanced methods based on biofeedback, transcranial brain stimulation system, and BCI system. The prevalence of neurological diseases, rise in technological advancement, the emergence of robotic rehabilitation, and the effectiveness of gaming systems in neurorehabilitation are factors that are propelling the demand of the global neurorehabilitation devices market. However, the shortage of skilled personnel, the high cost of treatment, stringent government regulation may hamper the global neurorehabilitation devices market. IMPACT ON PRICE Neurological rehabilitation is a program designed for the treatment of people suffering from a disorder or any injury in the nervous system. The devices include non-invasive brain stimulators, robotic neuro systems, brain-computer interfaces, and wearable devices, among others. Due to the pandemic, there is the delay associated with various types of limitations faced by the manufacturers to fulfill the end product order, which has resulted in the less availability of neurorehabilitation devices in the market and due to which the cost of available devices has increased with the several factors. Also, due to the coronavirus disease (COVID-19) pandemic outbreak, manufacturers are forced to find new contract manufacturers and suppliers for more manufacturing activities to different or new facilities locations that are less impacted by the outbreak. IMPACT ON DEMAND Neurorehabilitation is an important part of the recovery process that has undergone some brain injury. In the COVID-19 pandemic, various charities have worked effortlessly to provide treatment and support to patients suffering from brain injury. During the pandemic, the demand for neurorehabilitation devices was high, but companies were not able to supply the devices to end-users as various restrictions were imposed by the government, such as a travel ban, closed borders, among others. Coronavirus disease (COVID-19) is an infectious disease caused by a SARS-CoV-2 virus, while a large pool of the population is affected by this COVID-19 virus. Coronavirus disease (COVID-19) causes acute respiratory illness ranges from mild to severe pneumonia with respiratory failure. In order to minimize the spread of COVID-19, nearly all the countries have taken action, such as the implementation of lockdown and social distancing restrictions. Due to affirmative restrictions, sudden shrink took place in various surgeries. Moreover, the decrease in the revenue of the key market players depicted in their quarterly results, such as Medtronic, among others, gave evidence of the decline in the demand for the medical device due to the emergence of the COVID-19 pandemic. For instance, · Medtronic reported a decline of 1% in its brain therapies net sales of the financial results of 2020 as compared to 2019. The reduction was largely motivated by the detrimental effects of the COVID-19 pandemic and the subsequent deferral to companies of medical procedures The decline in revenue of brain therapy suggests the detrimental effect of COVID 19 on the neurorehabilitation devices market and hence impacted the demand-supply concept. IMPACT ON SUPPLY CHAIN The consequences of COVID 19 cannot be underestimated. The product and service providers of neurorehabilitation have made efforts by providing services virtually to meet the demands as people were not frequently visiting the hospitals or clinics for the treatment. The COVID-19 pandemic has transformed many organizations’ business environments; supply availability has been hampered by a number of issues, including export and travel restrictions by some manufacturing countries and lockdowns that have forced suppliers to (temporarily) shut down. In various countries, neurorehabilitation units have reduced their number of beds, in-patients and out-patient neurorehabilitation centers are restricted to a particular area in order to tackle the pandemic situation To manage such a critical situation, many organizations are looking forward to improving and diversifying the supply chain model in all aspects. Diversified supply chain model anticipated minimizing the export of medical devices as well as increase end-to-end visibility STRATEGIC DECISIONS BY MANUFACTURERS As the reality of COVID-19 dawned upon the world, the manufactures and production units of the companies in the global neurorehabilitation devices market swiftly planned for strategies to cope with the effect of the crisis. Major players in the market took various initiatives to cope up with the situation. For instance, · In July 2020, Abbott announced that it had received FDA approval for the use of the Patient Controller App on compatible personal Apple smartphone devices. The approval will allow the patient living with neurological conditions to manage their therapy directly from the personal smartphone · In 2019, Mount Sinai Health System announced an innovative tele-neurorehabilitation program for stroke patients. This therapy can be taken by patients while at their homes with virtual backing from clinicians · In 2020, Esko Bionics Holdings, Inc. announced that it had received FDA 501(k) go-ahead to promote its EksoNRTM robotic exoskeleton for patients with acquired brain injury. It is cleared by FDA for spinal cord injury, stroke, or acquired brain injury rehabilitation These strategies helped the company in coping with the pandemic and ensure business operations, minimize the impact of COVID-19, and providing full support to the government in their efforts to combat the disease and help the front-line workers. CONCLUSION The market is expected to decline due to increased restrictions imposed by various governments leading to the closing of non-emergent healthcare facilities, including procedures such as neurorehabilitation procedures. It can be concluded that the COVID-19 pandemic situation has an adverse impact on the market, affecting the price, supply, and demand of neurorehabilitation devices. However, in the crisis call, market players, government bodies, and healthcare organizations are work closely with healthcare professionals, customers, and patients for the betterment of public health. The increasing need of neurorehabilitation devices with increasing number of neurological diseases is expected to drive the market in coming years.
CBD for Sleep, CBD Benefits, Side Effects, and Treatment
People have long used the cannabis plant for medicinal and recreational purposes. Compounds called cannabinoids in the plant are responsible for the effects on the brain, and the two most abundant of these are tetrahydrocannabinol (THC) and cannabidiol (CBD). People use CBD for a variety of reasons, including reducing seizures, anxiety, and pain. Some studies have demonstrated that CBD may also be a sleep aid. In this article, we look at whether it works and any associated risks. What the research says In the last decade, growing public interest in the benefits of marijuana, and CBD in particular, has encouraged researchers to study its effects. Early studies indicate that high dosages of CBD may support sleep. One investigation found that, compared with a placebo, a CBD dosage of 160 milligrams (mg) increased sleep duration. The researchers also concluded that the placebo, 5 mg of the insomnia drug nitrazepam, and 40, 80, and 160 mg of CBD helped the participants fall asleep. The stress hormone levels of cortisol are typically peak in the morning, but people with insomnia may have high cortisol levels at night. Independent of insomnia, having high cortisol levels at night is associated with an increased nighttime awakening. In one study on the effects of CBD, researchers found that cortisol levels decreased more significantly when participants took 300 or 600 mg of CBD oil. These results suggest that CBD affects the release of cortisol, possibly acting as a sedative. A more recent analysis of CBD and sleep recruited 103 participants who had anxiety or poor sleep. The researchers studied the effects of CBD combined with those of other prescribed medications. The CBD dosages ranged from 25–175 mg. The researchers found that 25 mg was the most effective dosage for anxiety and that addressing troubled sleep required higher dosages. During the 3-month study, the investigators followed up with the participants monthly. At the first follow-up, 66.7% reported an improvement in sleep, but 25% had worsened sleep. 56.1% of the participants reported improved sleep at the second, but 26.8% had worsened sleep. The researchers conclude that although CBD might help people sleep in the short term, the effects may not be sustained. Side effects and other risks of CBD Overall, the available evidence suggests that CBD is well-tolerated. Some people report fatigue and mental sedation with CBD use, but researchers believe this may be related to the dosage. Taking 10–400 mg of CBD per day for an extended period and by different routes did not have a toxic effect on participants in a large retrospective study. Even dosages of up to 1,500 mg per day were well-tolerated, other researchers report. However, determining whether there are long-term risks of CBD use will require further studies. So far, no reports of lethal CBD overdoses exist. Some researchers may be concerned about CBD abuse, but information on significant complications is limited. One study indicates that dosages of 400–700 mg of CBD, which is considered high, can aggravate cognitive deficits in people with schizophrenia. Combining CBD and THC may, however, improve cognition. Researchers do report that CBD may cause other adverse effects, including: alterations of cell viability in studies conducted in cell cultures decreased fertilization capacity inhibition of drug metabolism in the liver reduced activity of P-glycoprotein and other drug transporters If these effects on drug metabolism and transportation are confirmed, it would indicate that CBD interferes with other medications. Overall, more research is necessary. Still, it is suitable for anyone who wants to use CBD to speak with a healthcare provider first. Check out the best CBD for sleep at Sweet Dream Beauty website.
How COVID-19 Impacted on Veterinary Vaccines in Healthcare Industry ?
COVID-19 Impact on Veterinary Vaccines in Healthcare Industry The animal health sector has witnessed significant developments over the past couple of years due to technological developments and efforts in Research and developments in veterinary sciences. One of the essential developments is antigen location using multiple bioinformatics methods and has been effectively used to immunize against various veterinary illnesses. Vaccines are a helpful to use way to protect animals against a variety of diseases. Vaccinology has produced several potent vaccinations that have significantly decreased the burden of certain severe illnesses in companion animals and cattle. Most approved veterinary vaccinations are available in live attenuated, killed/inactivated microorganisms, cell membrane compounds, or toxoids. The recent COVID-19 has an adverse the veterinary vaccines market as many animal drugs and vaccines were approved for human use. Animals infected with the virus have been reported all around the world. The majority of these animals, including a small number of domestic cats and dogs, got infected after coming into contact with people who had COVID-19. SARS-CoV-2 may infect companion animals like cats and dogs, large cats in zoos or sanctuaries, gorillas in zoos, mink on farms, and a few other mammals, but all of the species that can be infected in not been researched. Hence, the veterinary vaccines market is expected to play a vital role amidst the COVID-19 pandemic. IMPACT ON DEMAND The novel COVID-19 outbreak has led to a considerable rise in the demand for the veterinary vaccine. Veterinary offices worldwide made significant adjustments to guarantee that animals and livestock receive necessary veterinary care and that new safety procedures are in place to safeguard animals and veterinarians. As COVID-19 spread rapidly across the world and healthcare infrastructure became overwhelmed with COVID-19 cases. Coronaviruses can infect various domestic animals, including dogs, cats, cattle, pigs, and poultry. Routine vaccination can prevent many of these diseases. Vaccines against the canine coronavirus were in demand to protect puppies, although the illness is mild and self-limiting. In response to the surge in demand for veterinary vaccines, many veterinary producing companies were directed for the human COVID 19 vaccine, which impacted the production of veterinary vaccines. FOR INSTANCE- · In May 2021, Amid a shortage of COVID-19 vaccines as the country faces the second wave of infections, Bengaluru-based Institute of Animal Health and Veterinary Biologicals (IAH&VB) has offered to provide its state-of-the-art vaccine production facility to produce the vaccines IMPACT ON PRICE The veterinary services and vaccines prices were impacted due to COVID-19 up to some extent. Factors responsible for it were access to farming inputs, such as animal feed, livestock movements for pasture and water, animal equipment vaccinations, and other critical production inputs. Appeals to stay at home and social distance have had an impact on the pricing of veterinary vaccines. There been a whirlwind past months due to the emergence of COVID-19. The sale of some companies experienced a downfall while others managed to stay afloat. FOR INSTANCE, Common illness transmitted between species includes swine flu (H1N1), anthrax, and West Nile virus, to name a few. With more than 94.7 million cattle in the U.S. as of 2019 and more than 74.6 million pigs, the risk of zoonotic diseases transmitting to humans is a risk. It had an increase in prices for the veterinary vaccines IMPACT ON SUPPLY CHAIN The government throughout the globe imposed total lockdown, which led to supply chain disruptions. Consequently, the supply chain came to a standstill due to the closure of borders. Even though the demand for these devices was high, the availability was affected due to disruptions in the supply chain, trade, and travel restrictions. Supply of raw material was also affected, due to which the production was restricted. Veterinary services, such as routine vaccinations and testing and diagnostic instruments, were short supply for many farmers. As a result, animal illness control has emerged a new task that coincides with animal welfare concerns. However, the impact of COVID-19 on animal healthcare operations is not limited to the farm level; there are also national and international limitations. Due to funding constraints, several national and international animal health care programs/projects have been postponed or discontinued, limiting the success of disease elimination due to COVID 19. Several companies working on veterinary vaccines have indicated that the reductions in fluidity and foreign exchange were other significant factors affecting the sustainability of the livestock supply chain, specifically in developing countries during the pandemic. FOR INSTANCE: · The E.U. Executive Steering Group on Shortages of Medicines Caused by Major Events has provided strategic leadership for urgent and coordinated action to prevent and mitigate supply disruption during the pandemic The European Commission chairs the steering group. It consists of representatives of EMA, the European Commission, Heads of Medicines Agencies (HMA) and the Coordination groups for Mutual Recognition and Decentralised Procedures for human and veterinary medicines (CMDh and CMDv), as well as risk communication specialists PERSPECTIVE AND INITIATIVES: As the reality of COVID-19 dawned upon the world, the manufacturers and production units of companies involved in veterinary vaccines manufacturing industries and governments had various perspective and initiatives taken regarding the market. FOR INSTANCE: · In July 2021, Minister of Agriculture and Land Reclamation El Sayed El Quseir discussed investment in the production of veterinary vaccines and serums with Dr. Chris Nelson, Management Advisor of the Egyptian-American Middle East for Veterinary Vaccines (MEVAC) pharmaceutical company and President and CEO of the U.S. Kemin Industries · In July 2021, Zoetis donated more than 11,000 doses of its experimental COVID-19 vaccine to help protect the health and well-being of more than 100 mammalian species living in nearly 70 zoos, as well as more than a dozen conservatories, sanctuaries, academic institutions, and government organizations located in 27 states in new jersey CONCLUSION COVID-19 has impacted each sector with no exception. The veterinary vaccines market has been affected the same. With rising awareness around of vaccination against cattle diseases and improved health facilities for animal husbandry, there is a rise in demand for veterinary vaccines up to some extent. However, in the crisis call veterinary vaccine manufacturers, key players, government bodies, and healthcare organizations are working closely with healthcare professionals, customers, and patients for the betterment of animal health. Moreover, animal drugs and vaccines were approved for human use. Animals infected with the virus have been reported all around the world. Also, veterinary vaccine manufacturing facilities were used for production of human COVID vaccines around the worked. This is expected to impact the market for veterinary vaccines up to some extent.
Liposuction Vs. Non-Surgical Fat Removal
Many cosmetic surgery patients are concerned about areas of unwanted, diet- and exercise-resistant fat. Localized fat can be difficult to get rid of permanently, whether it appears as a persistent stomach "pooch" after pregnancy, areas of fat around the thighs that won't budge, or bulges along the flanks and back. For many years, liposuction has been one of the most popular and frequently performed cosmetic procedures, and for good reason. This surgical procedure reduces fat and refines body contours in a safe, effective, and permanent manner. Nonsurgical or minimally invasive alternatives to liposuction have grown in popularity in recent years. These body contouring treatments usually do not require an incision or anaesthesia, and they have a shorter recovery time. Continue reading to learn about the differences between the two fat-loss methods and to determine which one is best for you. What exactly is liposuction? Liposuction is a surgical fat removal procedure that rose to prominence in the 1980s. A board-certified cosmetic surgeon carefully and precisely removes excess fat during the procedure using a small, hollow tube called a cannula. As the surgeon moves the cannula through the fat deposit, suction is applied, removing excess fat cells and sculpting a slimmer body contour. Liposuction is especially useful for removing fat from the legs, abdomen, back, arms, face, and neck. It produces more dramatic results than other noninvasive fat reduction procedures; however, it requires a recovery period of about four weeks and is typically more expensive than nonsurgical alternatives. CoolSculpting®, BodyTite®, and Other Nonsurgical Procedures: How Do They Work? Nonsurgical fat reduction treatments employ a variety of modalities to target and eliminate unwanted fat cells via a topical, rather than surgical, procedure. Nonsurgical body contouring treatments that are popular include: CoolSculpting. Allergan's CoolSculpting is a good choice for people who are close to their ideal weight but want to reduce small, localised trouble spots on the hips, abdomen, or thighs. A specialised cryolipolysis device is used in this treatment to cool unwanted fat cells to the point of death without affecting surrounding tissues. Fat cells that have died are flushed from the body in the days and weeks following the procedure. After three months, the final result is visible. TruSculpt. Cutera's truSculpt treatment is similar in that it uses controlled radiofrequency technology to eliminate fat cells on the hips, thighs, buttocks, and abdomen. The average treatment lasts about an hour, and most patients require one to two treatments to see noticeable results. BodyTite. BodyTite by inMode is a minimally invasive procedure that uses radiofrequency energy to tighten skin and reduce unwanted fat deposits. An internal probe delivers thermal energy to help melt fat and strengthen collagen bands beneath the skin's surface, while an external applicator delivers radiofrequency energy to the skin for additional tightening. BodyTite is considered minimally invasive because a small incision is required to insert the internal applicator probe by your surgeon; however, it is a less invasive procedure than liposuction. BodyTite is an excellent choice for people who have small to moderate amounts of excess fat and loose skin and want to avoid the extensive downtime associated with surgery. Most patients report seeing results within a few days, with final results appearing after 2 to 3 weeks. Patients can expect to see continued skin tightening in the months following their procedure because BodyTite stimulates collagen production in the skin. SmartLipo. SmartLipo by Cynosure, also known as “laser liposuction,” is a non-surgical procedure that uses triple wavelength laser technology to remove unwanted fat around the muscles and tighten loose, sagging skin. SmartLipo's laser gets to work dissolving body and/or facial fat, which your body then processes and excretes naturally. To remove any excess liquid that may accumulate during the procedure, a very small tube is inserted into the treatment area. SmartLipo is ideal for areas of the face that traditional liposuction cannot adequately address, such as the jowls, chin, jaw, and neck, due to the small tube used. SmartLipo is also excellent for contouring areas of the body that retain stubborn fat, such as the abs, back, flanks, thighs, buttocks, and upper arms. Because SmartLipo is less invasive than liposuction, there is less tissue damage at the treatment sites. The results of SmartLipo treatment are visible immediately, and there is little downtime required. SculpSure. SculpSure by Cynosure is a non-invasive laser body contouring treatment that removes unwanted fat beneath the chin (submental fat), love handles, the back, the stomach, and the inner and outer thighs. SculpSure, like CoolSculpting and truSculpt, is ideal for patients who are nearing their ideal weight but want to reduce stubborn, exercise- and diet-resistant fat pockets. Unlike CoolSculpting, which freezes fat cells, SculpSure uses heat to destroy fat cells (a process known as apoptosis). SculpSure has been shown in studies to be effective at permanently removing up to 24 percent of fat cells in a treated area. A series of 25-minute treatments is beneficial to the majority of patients. Nonsurgical Fat Reduction vs. Liposuction Both liposuction and nonsurgical body contouring have advantages and disadvantages. Invasiveness Liposuction is a more aggressive method of fat removal that causes trauma in the treatment area. For up to 10 days after the procedure, patients will experience soreness, bruising, and swelling. CoolSculpting, truSculpt, and SculpSure treatments are typically gentle and cause little discomfort during and after treatment. Results Although the final result of liposuction is not visible until 6 months after the swelling has subsided and the treated area has healed. CoolSculpting and other noninvasive fat reduction treatments take longer to produce results, which become more visible in the weeks and months following the procedure. While neither liposuction nor nonsurgical body contouring treatments can replace weight loss, liposuction does provide more dramatic and longer-lasting results, as well as some skin shrinkage. Downtime The healing process after liposuction necessitates that patients limit their daily activities for several days following the procedure and exercise with caution. CoolSculpting, truSculpt, and SculpSure do not require a lengthy recovery period, and patients can resume normal activities right away, though mild soreness and swelling are to be expected. Though the results of nonsurgical fat reduction will be less noticeable, you will be able to return to work and resume your life much sooner. Is Liposuction or Nonsurgical Body Contouring the Best Option for Me? For larger deposits of excess fat, liposuction may be an excellent option. It has the potential to significantly improve your figure in multiple areas at the same time. Some disadvantages include a higher cost and a higher risk of health complications when compared to noninvasive techniques. If you are already at your ideal weight, have good skin elasticity, and want to target smaller, stubborn trouble spots, nonsurgical fat reduction may be a better option. The results, however, will not be as dramatic, and multiple treatments may be required. Making an Appointment for Liposuction or Nonsurgical Fat Removal The best way to decide between liposuction, CoolSculpting, truSculpt, BodyTite, and other non-invasive fat reduction procedures is to consult with a board certified cosmetic surgeon. During a personalised cosmetic surgery consultation, they can walk you through your options and help you decide which is the best fit for you.
How COVID-19 Impacted on Oral Care in Healthcare Industry ?
COVID-19 Impact on Oral Care in Healthcare Industry OVERVIEW The COVID-19 pandemic has posed a complex challenge in front of several healthcare companies and proved to be an unprecedented global health threat. This global pandemic has emerged in December 2019 which has been proved as a global pandemic by WHO in March 2020. With the development and introduction of novel coronavirus vaccine, COVID-19 cases have been declined but with the development of mutant coronavirus strain, the overall COVID-19 cases have been surged and are increasing at a rapid rate in India, and the U.K, and other European countries. The most common symptoms associated with this include cough, fever, diarrhea, sore throat, and loss of smell or taste. Patients affected with COVID-19 are at increased risk of developing hepatic manifestations and also experiences damage to liver tissues. COVID-19 has led to the closure and reduced hours of dental practices except for emergency and urgent services, limiting routine care and prevention. Dental care includes aerosol-generating procedures that can increase viral transmission. The pandemic offers an opportunity for the dental profession to shift more toward non-aerosolizing, prevention-centric approaches to care and away from surgical interventions. Direct effects of COVID-19 on oral health include ageusia (an official symptom of COVID-19) and case reports of vesiculobullous lesions and necrotizing periodontal disease. oral care product has a wide portfolio such as breath Fresheners, Mouth Wash, Dental Floss, among other products. The Article here shows the impact of COVID-19 on the oral care market. IMPACT ON PRICE As the mouth is an important place for bacterial colonization due to which it is necessary to use the product for oral hygiene. With the sudden increase in COVID-19 cases, people's concerns for better health had also increased and the link between oral health and COVID-19 infection also expand the health to oral. As India relies on China for 70% of API’s intermediates and bulk ingredients, COVID -19 is expected to hike the price of the ingredient used for an oral care product For instance, · In the year 2021, As Proctor & Gamble announced the third-quarter result in which the net sales increase by 5 %, and also mentioned that they are planning for a price hike in certain product divisions. This step is taken seeking to recover the revenue loss during COVID-19. · According to GlaxoSmithKline plc, the cost of dental consultation and treatment was cited as the concerning factor IMPACT ON DEMAND The coronavirus has affected the various regions of the world and caused the widespread closure of companies and local manufacturing plants. This lockdown and isolation have adversely impacted global economic activity. As studies around the world have shown the improving oral hygiene is expected to increase the chance of generating demand for the product. THE IMPACT OF COVID-19 INFECTION ON ORAL CARE The rising awareness of oral hygiene COVID-19 has increased the demand for a product requires for oral care as the increasing studies for SARS-COV-2 indicated that proper oral hygiene has been reported to decrease the chances of infection which increases the demand for mouth wash, oral povidone solution, novel gargle solution. · However, due to restrictions and aims to reduce COVID-19 transmission, 30% of respondents had visited a dentist less frequently during the pandemic The second cause of increasing demand for oral care products is that approximately 90% of the product used in oral care are over the counter which can be added as the plus point in maintaining the demand for oral care products. The market players in oral care are also focused on the research to bring novel products to interstate commerce. For instance, · Microbac Laboratories, an independent and internationally accredited testing facility worked on behalf of Unilever Research Laboratories, has found that rinsing with mouthwash containing CPC Technology for 30 seconds is effective in reducing the viral load of SARS-CoV-2, the virus that causes Covid-19, by 99.9%. This type of research surge the demand for the oral product · Colgate-Palmolive President mentioned in an interview that they have seen elevated demand for oral care related to viruses, which also boosted the innovative growth related to a premium product This suggests that the increasing prevalence of COVID-19 poses precautionary measures due to which the global population started to take concern for their health hence enhance the demand for oral care. This thus signifies that COVID-19 is accelerating the demand of the oral care market. IMPACT ON SUPPLY The COVID 19 pandemic has affected and badly disrupted the global drug supply chain due to the continuous shut down of manufacturing facilities and restrictions imposed by the government over import and export activities. As per global sources, it was found that the beauty care business is still facing a crisis due to COVID-19. However, oral care market players are in a strong position. The two main leaders Colgate-Palmolive and Johnson and Johnson had seen a lift in sales in Q1 2020. Colgate-Palmoliva has net sales of USD 415 million for Q3 2020, up by 5.5% from the previous year. The surge of demand for oral care increased during COVID-19 however, the global restriction, and state-wise travel restriction has caused challenges for the market player. Moreover, there are many local players also in the oral care market that continued to fulfill the demand in case of any disruption. Oral care is categorized under essential need products which leads to the easy flow of these products. The main challenges during the pandemic is the supply of API’s and Ingredient or excipient used in toothpaste, as China holds the major share in API’s and other chemicals used in oral care and global restriction has somehow affected the supply chain for these products too. This, thus signifies that due to continuous lockdown and several restrictions by government authorities the companies and patients are facing disruption of the supply chain for oral care. However, oral care is categorized under essential care which lowers the effect of supply chain disruption during COVID-19. STRATEGIC DECISIONS OF MANUFACTURERS Collaboration, agreements, strategic initiatives, product launches by market players such as Colgate Palmolive, Hindustan Unilever among others in the oral care market will help them to expand their product portfolio and to provide appropriate products to the consumer. This in turn will lead to increased product sales and hence will put a positive impact on the overall company’s revenue. Oral Care product manufacturing companies are taking so many strategic decisions to cope up with the current scenario of COVID-19. The companies engaged in the manufacturing of toothpaste, mouth wash, gargle solutions among others are adopting several initiatives to accelerate the development of newer products and efficiently supply the product to different end-users. Companies have done collaboration and product launches between 2019 -2020 which supports the sustainable growth in the oral care market For instance, · In September 2020, Colgate Palmolive launched as first-ever vedshakti mouth protect spray, seeking their focus on oral hygiene during COVID-19. · Hindustan Unilever also planned to launch a mouth wash with 99 % in reducing SARS-COV-2 virus and has recently shared the preliminary data. · In April 2020, GlaxoSmithKline Consumer Healthcare Limited (India) merged with Hindustan Unilever Limited (HUL), with HUL responsible for the distribution of GSK’s Consumer Healthcare brands in India, including its leading oral healthcare brand, Sensodyne. · In April 2020, Perrigo Company plc (Ireland) completed the acquisition of the oral care assets of High Ridge Brands (US), which includes Dr. Fresh, LLC. · In December 2019, Colgate-Palmolive Company launched Colgate Optic White Renewal Tooth Paste. · In 2020, Colgate-Palmolive comes up with a recyclable toothpaste tube which will increase the interest of the population and surge the demand for the product leading to growth in revenue of the company Thus, companies operating in the oral care market are adopting several strategies, including collaboration, agreements, acquisition, and market expansion to enhance their business. These strategic decisions by the companies are expected to provide significant opportunities for the market players operating in the oral care market. CONCLUSION As the pandemic of COVID-19 has resulted in several restrictions throughout the borders but still, manufacturers of oral care can manage their stocks. Various manufacturers have allowed their manufacturers to work in a clean and safe environment to boost up the production of oral care categorized under essential need products at various manufacturing facilities across several regions of the world helping them to maintain a continuous supply chain. However, a decrease in doctor’s visit has impacted the market but the majority of products used in oral care are over the counter product which leads to continuous demand for oral care, and by raising the prices the companies are gaining extra profit which is helping them to combat the negative effect on overall revenue.
How COVID-19 Impacted on Niemann-Pick Disease in Healthcare Industry ?
COVID-19 Impact on Niemann-Pick Disease in Healthcare Industry OVERVIEW A novel coronavirus, SARS-CoV-2, appeared in December 2019 in Wuhan, China, spreading much faster than its predecessors and has already infected millions of patients worldwide as of April 19, 2020. As the scope of the current COVID-19 outbreak has reached the proportion of pandemics, significant international efforts in public health are underway to control the epidemic. The covid-19 pandemic majorly impacted the rare diseases patients because, during the pandemic, the need to provide high-level care for a large number of patients with COVID-19 has affected resourcing and limited the routine maintenance of all other conditions. The impact of health emergencies particularly faced by the rare disease communities, organizations, clinics, and other healthcare providers. The health economic challenges faced by patients and their families, institutions, research organizations, and healthcare providers during the pandemic outbreak have demonstrated the importance of ensuring continuity of care in the management of rare diseases, including adequate diagnostics and monitoring protocols, and highlighted the need for a structured emergency strategy. Niemann-Pick disease is a rare, inherited disease that affects majorly body's ability to metabolize fats such as cholesterol and lipids within the cells. Over time, these cells got malfunctioned and died. The disease can affects the brain, spleen, nerves and, if get severe, may affect lungs, bone marrow, and other organs. The disease can occur at any age but majorly affects children. There is no known cure for the disease, and sometimes it may be fatal for children, the only treatment is focused on helping people live with their symptoms. IMPACT ON PRICE Various market players are facing a large number of challenges due to the coming of the novel coronavirus and different strains; one such issue is the uncertainty surrounding the impact of covid-19 on off label drugs demands. Due to the increased coronavirus cases and continuous lockdown, the costs of the drugs and their APIs increase automatically. On the one side, it will increase the revenue of the companies, but a patient may resist buying the products, which ultimately increases the stress level on the patients. Moreover, Due to the pandemic, there is the delay associated with various types of limitations faced by the manufacturers to fulfill the end product order, which has resulted in the less availability of medical devices in the market and due to which the cost of available devices has increased with the several factors. Also, due to the Coronavirus disease (COVID-19) pandemic outbreak, manufacturers are forced to find new contract manufacturers and suppliers for more manufacturing activities to different or unique facilities location that are less impacted by the outbreak. The impact of Covid-19 has created huge price impact on the government as well as on patient families that they have to buy the drugs on higher rate as compared to the average rate. IMPACT ON DEMAND The Coronavirus zone is the result of various markets around the world. This is the cause of the widespread closures and isolation that are affecting world economic activity. As the cases increases in the month of April 2020, the sudden surge in demand has seen, and drugs and medical devices went out of stock. Moreover, the decrease in the revenue of the key market players depicted in their quarterly results, such as Medtronic, among others, gave the evidence of decline in the demand for medical devices due to the emergence of the COVID-19 pandemic. For instance, · Medtronic reported a decline of 1% in its brain therapies net sales of the financial results of 2020 as compared to 2019. The reduction was primarily motivated by the detrimental effects of the COVID-19 pandemic and the subsequent deferral to companies of medical procedures. · Impact on rare disease organization also faced significant fundraising income loss, this consequential income loss may leads to loss of various people jobs associated with the organizations. The cutting or income loss leads to the reducing staff, canceling offices leases, and delay or cutting office programs. The impact of covid-19 majorly impacted the organizations if the revenues loss projections do not change, this will leads to temporarily or permanently shut down of small and middle foundations and organizations. IMPACT ON SUPPLY As the epidemic intensifies, supply chains can be at significant risk due to over-located locations that can potentially be disrupted. The supply chain of drugs, devices, and services has been disrupted. The spread of COVID-19 makes it difficult for governments to use these drugs; the availability of these systems faces constant challenges due to their components of use and limited initial needs. Moreover, as there is no cure for the disease, only physical activities/therapies may suppress the symptoms also affected by pandemics. According to the NORD (National Organization for Rare Disorders), in the U.S. stated that 74% of the population have had canceled medical appointments due to Covid-19 pandemic, 69% of population concerned about their medication and medical supplies. For instance, • In June, ResMed stated that, due to the Covid-19 pandemic company sleep apnea business segment adversely affected including sleep clinics, physician practices, HME suppliers. As new patients are prescribed sleep apnea devices such as PAP, CPAP devices for the treatment through hospitals that are directing their resources to critical care, including COVID-19 treatment. The covid 19 impacts may continue to decrease demand for the sleep apnea devices sale STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS As such, market participants are involved in the production of drugs, expanding their business through a variety of programs, including collaboration, contracts, and pipeline development, collaboration, and market expansion. It is expected that the strategic decisions of these companies will provide significant opportunities for market participants operating in the Niemann-Pick Disease market. For instance, · In July 2020, Abbott announced that it had received FDA approval for the use of the Patient Controller App on compatible personal Apple smartphone devices. The approval will allow the patient living with neurological conditions to manage their therapy directly from personal smartphone. · In May 2020, Philips, a global leader in health technology, joined forces with the American Telemedicine Association (ATA) to help further the adoption of telehealth across the industry, demonstrating its commitment to connecting care across acute, post-acute, and home care settings. The continued collaboration spotlights telehealth's growing adoption and momentum amidst COVID-19 and the need to convey the exponential shift to telehealth capabilities. · In U.S., NIH supports the research survey of “CURE EPILEPSY ORGANIZATION” to examine the impact of Covid-19 on Rare Disease Community. The survey includes more than 200 rare diseases including the brain, immune system disorders, heart, lungs, brain development diseases, and more. CONCLUSION As this pandemic situation has resulted in many restrictions in different places around the world, still the market players of dealing in rare diseases therapy and services were able to manage their service stock. Different companies dealing in metabolic diseases therapy services were finding out their own way to deal with this pandemic situation. The government and companies around the globe are working together and have issued advice for those undergoing therapies centers during these unprecedented times during COVID 19 lockdown around the world. The supply chain was destroyed, but several steps were taken by the government and companies, which will help them, get their needed output for therapy service. By increasing the material price, the companies can maintain their overall revenue. Thus, different foundations, organizations,, and services center markets are finding ways to deal with this pandemic situation. Figure 1: Relationship between Coronavirus and Lysosome storage diseases : Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway
Lupin For Chronic Disease
Why You Need Lupin For Chronic Disease Management Heart disease, diabetes, stroke, and other chronic diseases are the leading causes of disability and death in Australia and many countries all over the world. With modern lifestyles and unhealthy food products, chronic diseases escalated and are now one of the biggest health challenges. About 50% of Australians suffer from chronic diseases and 9 out of 10 deaths associates with them. While chronic diseases are common and deadly, many of them are still preventable. Lifestyle choices altered at any time cause most chronic diseases. By maintaining a healthy diet, becoming more physically active, and avoiding tobacco, you can stay safe from these diseases. And, even if you already have an existing condition, changing your lifestyle and eating habits can help you better manage your disease, avoid complications and extend your life. Since the food you eat has a huge impact on your ability to prevent or manage chronic diseases, you need to pick your meals carefully. It's your best chance at living a long and painless life. One of the foods that can help you successfully deal with long-term and incurable illnesses is the healthy legume called lupin. Below is some background information about lupin and why you need lupin for chronic disease management. What Is Lupin? Lupin is a yellow bean coming from the legume family, closely related to soybeans and peanuts. It contains high amounts of protein, fibre, and a multitude of essential vitamins and minerals. Lupin is also non-GMO, low carb, low GI, and gluten-free, which is an advantage to vegans, celiacs, and keto dieters. Although only recently recognised as one of the best superfoods in the world, lupin has been around for centuries. The earliest known consumption of lupin can be traced back to early Mayan and Egyptian civilizations. Some countries in the Mediterranean regions, Latin America, and North Africa have continued their use through the years. However, because of its bitter and toxic qualities, the popularity of early lupin varieties did not take on. Europe and Australia bred this is a newer and sweeter cultivar. Today, lupin is found across different countries and continents, with most of the sweet lupin crops originating from Australia. Lupin is not only distributed in its raw form but also as processed healthy products such as lupin flour and lupin beans. How Can Lupin Fight Chronic Diseases? A small but powerful legume, lupin can help promote wellness and alleviate health problems. This includes the prevention and treatment of chronic diseases and their symptoms. The protein extracts of lupin help relax the blood vessels, which assists in lowering blood pressure, sugar, and cholesterol levels. Because of this, the risks of hypertension, heart attack, stroke, paralysis, and diabetes can be reduced. Recent studies also found that the lupin proteins called conglutins could help reverse the harmful effects of inflammatory diseases at several stages. Some studies even claim that lupin proteins can help cure type 2 diabetes, by effectively controlling the level of insulin that the body produces. Besides that, lupin is rich in valuable nutrients that help optimise body processes, prevent infections, and fight other illnesses. Is Lupin Safe For Everyone? Lupin is generally safe to consume, even for those in the late stages of chronic conditions. However, it could cause allergic reactions to a small population. If you are allergic to peanuts, there's a chance you might also be allergic to lupin. But, aside from allergens, lupin contains all-natural non-harmful substances that far outweigh its risks. Nevertheless, if you experience any unusual reactions after eating lupin, call your doctor immediately. With the alarming number of Australians with chronic diseases, knowing lupin and other helpful foods that can help counter them is absolutely important. If you want to learn more about the uses of lupin for chronic disease and how you can add it to your healthy meals, browse through The Lupin Co. website. Here, you can buy lupin and find helpful information that can help you further understand why you should start bringing it into your diet. You can also speak with us directly by calling 08 6263 1140 or emailing at enquiry@thelupinco.com.au.
Healthcare EDI Market worth $4.4 billion by 2025 - Exclusive Report by MarketsandMarkets™
According to the new market research report " Healthcare EDI Market by Component (Solution, Service), Delivery Mode (On-premise & Cloud, Mobile) Transaction Type (Claims Management, Payment Remittance, Payments, Healthcare Supply Chain), End-User & Region - Global Forecast to 2025", published by MarketsandMarkets™, the market is projected to reach USD 4.4 billion by 2025 from USD 3.0 billion in 2020, at a CAGR of 7.8% during the forecast period. Browse in-depth TOC on "Healthcare EDI Market" 129 – Tables 44 – Figures 195 – Pages Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=130571438 The growth of this market is majorly attributed to the development of regulations for transaction processes, the rising need to curtail healthcare costs and government support for HCIT implementation. Also, the need for the efficient management of electronic claims and reimbursement transactions (for healthcare providers) is expected to drive demand growth in the healthcare EDI market during the forecast period. By delivery mode, the mobile EDI segment is expected to grow at the highest growth rate during the forecast period Among the delivery mode segment, the mobile EDI segment is expected to grow at the highest CAGR during the forecast period. The factors attributing to the high growth of this segment include the technological upgrades in the healthcare industry and growing acceptance of mobile solutions among healthcare providers. By component, the services segment is expected to record the highest CAGR during the forecast period The services segment is expected to witness a faster growth rate in this market due to factors such as, the increasing claims volume, increasing complexity, and scale of EDI solutions, as they require extensive training programs. Similarly, a growing trend of outsourcing activities, such as revenue cycle management, claims handling and management, and partner management services is also expected to propel the growth of the services market. By transaction type, the claims management segment is expected to account for the largest share of the healthcare EDI market On the basis of the transaction type, the EDI market is segmented into claims management and healthcare supply chain. The claims management segment is expected to account for the largest share of the market during the forecast period. The large share of this segment can be attributed to the rising adoption of EDI services by healthcare providers and payers and the need to meet regulatory requirements. By end user, the healthcare payers segment to record the highest CAGR during the forecast period Based on end user, the healthcare EDI market is segmented into healthcare providers, healthcare payers, medical device & pharmaceutical industries, and pharmacies. The healthcare payers segment is expected to grow at the highest CAGR during the forecast period due to the increasing number of private insurance players in the market. Get 10% Customization on this Research Report: -https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=130571438 North America dominates the Healthcare EDI market during the forecast period. North America is expected to hold the largest market size in the global market during the forecast period, followed by the European region. The rising HCIT expenditure, developed healthcare infrastructure, broad insurance coverage, a favorable regulatory scenario, an increasing number of private healthcare players, growing demand for healthcare supply chain management solutions, and the presence of prominent healthcare IT companies in this region, are responsible for the large share of the North American EDI market. McKesson Corporation (US), Optum (US), Allscripts Healthcare Solutions Inc. (US), athenahealth (US), and Nextgen Healthcare (US) are the key players operating in the healthcare EDI market. Other prominent players in this market include Cognizant Technology Corporation (US), SSI Group, LLC (US), Cerner Corporation (US), Comarch SA (Poland), Axway Software SA (France), Optum Inc. (US), Dell Technologies Inc. (US), Nextgen Healthcare (US), Synnex Corporation (US), Comarch (Poland), Axway Solutions (US), and Plexis Healthcare Systems (US). Browse Related Reports: Revenue Cycle Management/RCM Market by Product & Services (Eligibility Verification, Clinical Coding, CDI, Claims Processing, Denial Management, Outsourcing Services, Cloud), End User(Payers, Hospitals, Outpatient), Covid-19 Impact - Global Forecast to 2026 https://www.marketsandmarkets.com/Market-Reports/revenue-cycle-management-market-153900104.html
Significant Impact of COVID-19 on Hot Fill Packaging in Food & Beverage Industry
COVID-19 Impact on Hot Fill Packaging in Food and Beverage Industry The COVID-19 pandemic has affected the industrial and commercial progress of most of the regions in the world. The persistence of the COVID-19 for a longer period has adversely affected the most vulnerable groups of the population including adults aged more than 60 years, mothers, and children. Globally, countries are expecting a drastic decline in dietary quality in low- and middle-income countries as a result of loss of income, the shutdown of businesses, human and goods movement restrictions imposed by governments, de-globalization, and breakdown of the supply chain of food markets due to both demand shocks and supply constraints. Healthcare facilities have been consistently giving their best to combat COVID-19 and helping resources to divert from nutritional care including micronutrient supplementation, prevention, and treatment of child malnutrition. In normal times, malnutrition remains a multidimensional problem and during the pandemic situation, it has taken a major hit. Thus, the population will be more focused on building higher immunity levels during the post-crisis situation. Furthermore, due to COVID-19, supply, import-export, and demand have been affected as there was less supply the prices of food products and that impacted the demand of the global hot fill packaging market. However, manufacturers are trying to build new strategies to cope with the situation. Every sector in the food industry has been impacted either positively or negatively due to the COVID-19. The hot fill packaging market has positive as well as negative impacts in some of the aspects of the COVID-19 outbreak. The COVID-19 pandemic has introduced a change in eating habits, disruption in the supply chain which affected the market adversely. AWARENESS ABOUT CLEAN AND HEALTHY FOOD INCREASED DUE TO THE COVID-19 PANDEMIC According to the health safety evidence coronavirus appear to be stable at low and freezing temperatures on food surfaces for a certain period, however food hygiene and good food safety practices can prevent their transmission through food. The best practice for food business operators and consumers is to maintain the highest standards of personal hygiene, food hygiene, and the standard protocol of social distancing and limiting social contact, and detecting /isolating the infected persons from food handling operations. World Health Organization (WHO) has advised social distancing and maintaining high personal hygiene standards and food safety as a means of containing and stopping transmission of this virus. Thus, consumers are demanding healthier and safe food to avoid the disease. The food product is cooked thoroughly and then filled into a container during hot filling processes. Products are heated to temperatures above 85°C (185°F) and filled into a given container to ensure a safe product. Once the container is filled and sealed it can be inverted and held in the air for three minutes before being cooled by water. Inverting of the package is done to pasteurize the headspace and lid, this method has been used in industry for filling into glass jars, plastic trays, cartons, and pouches. Thus the rise in demand for preservative-free products helps in increasing the shelf life of the product and rising awareness regarding the benefits associated with the usage of hot fill packaging. The adoption of economical as well as simpler processes will likely enhance the growth of the hot fill packaging market in the forecast period. Thus, due to the safety, sterilization, and sanitization of food with hot-fill packaging, the demand is increasing worldwide, and manufacturers also trying to launch new techniques and products to fulfill the demands of the consumers. For instance, · The below pie chart shows the consumption of packed beverages in 2020 Thus, it can be concluded that the consumption of packed food has been increased to ensure food safety which is adding to the growth of the global hot fill packaging market. COVID 19 IMPACT ON SUPPLY CHAIN OF HOT FILL PACKAGING The supply chain plays a major role when it comes to the sale of food products and due to the persistence of COVID-19, the supply chain has been disrupted worldwide. With the persistence of COVID-19, there have been restrictions on transportation, import, and export of food products. Furthermore, with the movement restriction on workers as well, the manufacturing of hot fill packaging and its products has been affected due to which the demand for consumers has not been fulfilled. Also, with restriction on import and export, it made difficult for the manufacturers to supply their products to various regions which also has impacted the prices of hot fill packaging. Thus, with ongoing restrictions due to COVID-19, the supply chain for the hot fill packaging market has been disrupted which is creating a major challenge for the market. The persistence of COVID-19 and restrictions on movement is disrupting the supply chain worldwide which is posing a major challenge for the global hot fill packaging market. However, manufacturers are trying to sell their products on digital platforms to cope up with the situation and hence getting positive responses from the consumers. For instance, · United States Plastic Corporation has the facility of their latest website technology, product tracking system, and order fulfillment equipment. The company says that “We hold nothing back when it comes to delivering quality products to our customers in an expeditious manner.” INITIATIVES Pipeline Packaging is one of the prominent players in the hot fill packaging industry. The company focuses on expanding its product manufacturing capacities, to cater to the large customer base to develop new products and also has taken initiatives in COVIID -19. CONCLUSION COVID-19 outbreak has affected every sector in the market which includes the hot fill packaging market. Some companies have closed their production facilities to mitigate potential risks from COVID-19. However, the demand for hot fill packaging has increased due to its benefits regarding food safety. Many researchers and manufacturers are urging governments to build awareness about safe and packed food. Manufacturers are introducing new techniques and innovations to increase food safety and thus the business. This is significantly affecting the global hot fill packaging market. Thus, the hot fill packaging market will mark sudden surges in demand during the COVID-19 pandemic and is projected to significantly grow over a long period due to permanent changes in consumer buying behavior.
Significant COVID-19 Impact on Nivolumab in Healthcare Industry
COVID-19 Impact on Nivolumab in Healthcare Industry COVID-19 (Coronavirus) has affected the day-to-day life of people and has slowed down the economies worldwide. The pandemic has affected millions of people who either got sick or died due to the spread of this disease. Within a few months, coronavirus disease (COVID-19), which originated from China, became a pandemic, with more than 30 million people being infected till date. There are now numerous vaccines in use. The first mass vaccination program commenced in early December 2020, and as of 15 February 2021, 175.3 million vaccine doses have been administered. There is an added complexity because of COVID-19 diagnosis in cancer patients, particularly while on active treatment with immunotherapy like nivolumab. COVID-19 could cause more harm to cancer patients. In order to prevent the infection from spreading, the patient’s number and new diagnosis have been less during the COVID 19. The COVID-19 pandemic has led to a dramatic loss of human life worldwide and presents an unprecedented challenge to public health, food systems, and the world of work. Still, there is an increase in the demand for cancer treatment with immunotherapy drugs like nivolumab during the second quarter of 2020 with the rise in awareness regarding health and new product launches in countries. IMPACT ON PRICE COVID-19 is significantly decreasing commercial activity in every area of the business sector. The economy has been decreased during the pandemic with the restricted and disrupted supply and sales of products and devices. The cost of medication and treatment of nivolumab has been increased due to the increasing demand for this drug during COVID-19. This contributed to the increased expenses and prices of immunotherapy drugs. Changes in the economy and other factors have caused consequences, including the decrease in the sales of the drug in some countries such as the U.S. With the rise of COVID-19 and decrease in new patients has also contributed to the increased cost and priced of some products and medication. · The price of Opdivo (nivolumab) drug which is a most common therapy treatment for various type of cancer or tumor have been increased to USD 1,172 for a supply of 4 milliliters of injection in 2020 with the rise in demand and increasing patients population in the second quarter of 2020. IMPACT ON DEMAND Global economic development in 2020 has been severely impacted by the COVID-19 pandemic. The COVID-19 has given rise to risks such as a prolonged, significant decline in global demand as well as unfavorable geopolitical and macroeconomic effects. The coronavirus pandemic has provoked many strategical actions among healthcare providers on how to manage cancer patients when faced with the threat of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection. There has been a decrease in demand for nivolumab in some countries like the U.S., whereas many countries have seen an increase in sales with the rise in demand for the treatment and new cancer patients. With the rise in demand for the drug, FDA has provided approval to various drugs related to the immunotherapy nivolumab. For instance- · For the Bristol-Myers Squibb Company, the U.S. revenues of nivolumab decreased to 9% in 2020 due to lower demand caused by declining second-line eligibility across tumor indications and lower demand from COVID-19 (primarily lower new patient starts and patient visits). The U.S. has seen a decrease in sales in the first quarter of 2020. · However, the international revenues for nivolumab were increased up to 7% in 2020 due to higher demand as a result of additional indication launches in some countries with rising cancer patients globally. · In May 2021 -- Bristol-Myers Squibb Company has today announced that the U.S. Food and Drug Administration (FDA) had approved their Opdivo (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer. · Similarly, FDA has approved Opdivo (nivolumab) for treating different types of cancer in many countries via various market players due to the rise in demand for this drug. IMPACT ON SUPPLY CHAIN The pandemic and COVID-19 have affected every business activity in which the supply chain was affected the most. Because of the pertinacious COVID-19 lockdown, sanctions have been forced by administrations of different nations. These limitations and boundaries across the nation’s borders prompted a diminishing stockpile because of restricted materials and labor force and the halting of the assembly line. The COVID-19 pandemic has transformed many organizations’ business environments; supply availability has been hampered by a number of issues, including export and travel restrictions by some producing countries, and the lockdown has forced suppliers to (temporarily) shut down. The supply of nivolumab medication has a slight decrease in sales during the first quarter of 2020, partly due to negative factors mentioned above in connection with the COVID-19 pandemic, which particularly didn’t affect the overall yearly revenue. The supply chain and demand were positively affected by the COVID 19. The sales and supply of the drugs have been increased with the rise in demand for the drugs and diagnosis. Many major manufacturing companies have launched their drugs in different countries to fulfill the demand, and the government has provided approval for the sales of the drug nivolumab. For instance- Despite the pandemic, many market player of nivolumab has increased their sales globally. This is due to the ongoing increase in the patient population and rising awareness regarding their health. · The sales of ONO pharmaceuticals have been increased in the year 2020 as compared to 2019, which is 2656.05 USD Million in 2019 and 2809.23 USD million. · Similarly, sales of the drug Opdivo (Nivolumab) from the manufacturing company Bristol Myers Squibb Company have been increased globally (except the U.S.) from USD 2,860 million in 2019 to USD 3,047 million in 2020. This increase in sales in both of the major market players is due to the increase in cancer patients and the use of drugs in all areas of cancer. There is an increase in the sales of this nivolumab with the rise in prevalence of disease and early diagnosis & treatment. STRATEGIC DECISIONS BY MANUFACTURERS To deal with the COVID-19 outbreak challenges and increasing demand for the drugs, many market players are creating new strategies such as new product development, telemedicine, and a different program to support patients and to raise their sales. It is predicted that these strategies are anticipated to escalate up the company revenue and its growth in the forecasted period. The government has provided drug FDA approvals of nivolumab for the treatment of cancer. For instance, · In May 2020, Bristol Myers Company announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). · There are several ongoing potentially registrational studies that have been conducted by different manufacturing companies for Opdivo for the treatment of different tumor types and disease areas, in combination with various anti-cancer agents · Also, there are various ongoing clinical trials conducting on nivolumab with the combination of various anti-cancer agents and others to treat various types of cancer to decrease the demand for cancer treatment and to provide patients with more advanced drugs. For instance · In Japan, South Korea, and Taiwan, ONO pharmaceuticals are co-developing this drug nivolumab with the Bristol Myers Company CONCLUSION As the pandemic of COVID-19 resulted in several restrictions throughout the borders, still, manufacturers and market players were able to manage their sales and revenue of oncology and drug nivolumab. Various manufacturers allowed their workers to work in a clean and safe environment so as to boost up the production at various manufacturing facilities across several regions of the world, thus, helping them to maintain a continuous supply chain with the increasing demand. Market players have come up with better strategies which have also created a positive impact on the growth of the nivolumab market globally.
Significant Impact of COVID-19 on Absorbable Heart Stent in Healthcare Industry
COVID-19 Impact on Absorbable Heart Stent in Healthcare Industry Coronavirus disease 2019 (COVID-19), also known as SARS-CoV-2 or 2019-nCoV, is a human infectious disease caused by the coronavirus that causes severe acute respiratory syndrome. COVID-19 was declared a pandemic by the world health organization due to the rapid rise in human infection rates. The COVID-19 pandemic has influenced the whole planet with its major impacts on the economy and businesses across the globe. Though the emergence of the virus can be traced back to Asia, many European countries along with the U.S. have been struck massively by the pandemic. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, Middle East, and Africa up to South America. After the declaration of the pandemic, various countries announced the complete lockdown such as India, China, and other Asian countries to decrease its spread. According to the latest situation report by World Health Organization (WHO) stated 175 million cases of corona virus have been reported globally and 4 million patients are dead due to the coronavirus. On a slightly positive note, a total of 158 million people have recovered and a total of 2 million vaccine doses have been administered. On March 11, 2020, the World Health Organization declared the coronavirus COVID-19 pandemic. Coronavirus disease 2019 (COVID-19) is a worldwide pande0mic, and cardiovascular complications and arrhythmias in these patients are common. Cardiac monitoring is recommended for at-risk patients. The novel coronavirus pandemic has significantly impacted the timely delivery of surgical or stent treatment for patients with severe coronary vascular disease. This has created a large backlog of work and upstaging of disease with consequent increase in risk and cost of treatment and potential for worse long-term outcomes. As countries emerge from lockdown but with COVID-19 pandemic in society, precautions remain that restrict ‘normal’ practice. Stents are small, expandable tubes that treat narrowed arteries. Coronary artery stents are used to open the blockage of arteries or to expand the narrowing arteries, which helps to treat a heart attack, and reduce pain like chest pain. Absorbable Heart Stents are said to be “the fourth revolution” after balloon angioplasty, baremetal stents, and drug-eluting stents. As these provide mechanical support for a determined period and then disappear from the vessel, allowing its natural healing, and avoiding the risks associated with having a permanent metallic cage, such as stent thrombosis. The absorption of the stent could potentially lead to a recovery of the endothelial function of the vessel, making it responsive again to vasoactive agents. The potential benefits, including the decreased risk of stent thrombosis at long-term follow-up, one of the most feared complications of metallic stents, have led to absorbable stents, a field of growing interest in interventional cardiology. The increasing prevalence of geriatric population and adoption of sedentary lifestyle along with the rise of obesity in people are driving the absorbable heart stent market as coronary artery diseases require appropriate surgeries for 'their treatment’. But there is a negative impact of COVID-19 on the absorbable heart stent market due to massive disruption of supply chains, and financial fragility forced manufacturers to shut down their industries as absorbable stents require high financial inputs for manufacturing. For Instance, · According to the Center for Disease Control and Prevention (CDC), about 18.2 million US adults age 20 and older have CAD (about 6.7%), which has required appropriate treatment · According to the European Cardiovascular Disease Statistics 2017, each year, cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU) Moreover, COVID-19 has made it more challenging for the manufacturing companies to bridge the losses and attempt to fulfil the demands during these times. The COVID-19 has impacted the business of manufacturers, and other service providers that are involved in absorbable heart stent devices. IMPACT ON PRICE COVID-19 has forced the countries to impose lockdown and restrictions worldwide. This has affected many industries and economies. The total lockdown in various countries forbade the transportation of raw materials, and the business of service providers. So, manufacturing absorbable heart stent devices has become difficult, which directly impacted the prices largely. For instance, · In 2020, National Pharmaceutical Pricing Authority (NPPA) has been approved to hike the prices of absorbable heart stent on seeing the current scenario and making it easy for the manufacturers. IMPACT IN DEMAND The outbreak of the coronavirus has shown impacts on various markets around the world. It is the cause of lockdown and isolation, which ultimately has an impact on global economic activity. This is why the global epidemic has shrunk by 1.0% in the current year. Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. As heart patients are under suspection for higher exposure to COVID-19, demand for absorbable stents surges as companies are making efforts to provide help to healthcare systems to overcome the scarcity of stents while treating CAD. Absorbable stents are in high demand due to the high prevalence of interventional cardiology and peripheral vascular procedures amid the COVID-19 pandemic, which prevents the patient from staying in the hospital for long. The clinical observations suggest that a person with heart disease has been more prone to COVID-19, which lead to clinical complications. Therefore, the government of various countries laid guidelines for special care, and treatment for heart patients. This has surged the demand for absorbable stents among people for early treatment of CAD to prevent complications of COVID-19. For Instance, · According to an early bulletin released by the American College of Cardiology (ACC) on March 6, 2020, people who have underlying cardiovascular disease, have a higher mortality rate when it comes to COVID-19 (10.5 percent) than people who have an underlying chronic respiratory disease (6.3 percent) · According to the American Journal of the Medical Sciences, the COVID-19 mortality rate for people with pre-existing cardiovascular disease was between 10.5 and nearly 14 percent, and the number surged to between 35 percent and almost 87 percent for people who had underlying coronary artery disease IMPACT ON SUPPLY CHAIN The COVID-19 outbreak has disrupted the supply chains for absorbable heart stents globally. The sudden outbreak of COVID-19 and its subsequent impact on restrictions on trade and development of goods has resulted in a shutdown of vast portions of the global economy, resulting in disrupted supply chains due to transportation cessation, which affected the manufacturing unit largely. Companies in the arterial stents market are helping healthcare systems to stock inventory and medical devices in order to avoid supply shocks amidst the COVID-19 pandemic. For instance, · According to FDA, there have been reported shortages of medical devices and equipment amid COVID-19 due to disruption of supply and service providers · According to Springer, 2020, many companies experienced dramatic exposure to supply chain disruptions during the pandemic and the subsequent lockdowns (Strange 2020) due to their reliance on offshore supplies STRATEGIC INITIATIVES FOR MANUFACTURERS A large pool of the population affected by this COVID-19 virus, and its spread is expanding across the world in the last few months. To deal with the COVID-19 outbreak challenges, many market players are creating new strategies. The key players engaged in providing products such as Medtronic, Boston Scientific Corporation, Abbott, Cook Group, Angiomed GmbH & Co. Medizintechnik KG face challenges to keep the growth during coronavirus and to maintain the demand and supply chain with proper protection of the employees. For instance, · Medtronic focused on providing special protection and care to its employees. Its manufacturing and distribution facilities are routinely cleaned and sanitized, employees are utilizing personal protective equipment (PPE) and social distancing, including staggered breaks to reduce crowds in common areas, and additional screening and access protocols have been implemented. · Medtronic increased contributions to its Employee Emergency Assistance Fund, which is providing need-based financial grants to employees who are experiencing economic impact due to the COVID-19 pandemic, including childcare reimbursement. · Boston Scientific Corporation is providing extra precautions, including increased cleaning measures, social distancing protocols, and the use of face coverings for employees who work onsite, along with personal protective equipment (PPE) for employees in the workplace ensuring business continuity. CONCLUSION The COVID-19 has impacted the market positively. To summarize, the prices for this market has increased as manufacturing requires raw materials which have been disrupted amid COVID-19. The demand for absorbable heart stent market has been increasing due to the prevalence of geriatric population and adoption of sedentary lifestyle which leads to various coronary vascular diseases, but the supply chain and service providers are unable to satisfy the needs, and thus, have impacted largely. However, manufacturers, service providers, and the government are making new guidelines to work safely in the workplace in the new normal and combat the gap between demand and supply. Overall, various measures have been taken by the market players to improve their business and the quality of their services.